Display options
Cite
Sjöstrand M, Wei C, Cook W, et al. Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. Diabetes Ther. 2017;8(3):587-599doi: 10.1007/s13300-017-0261-8.
Sjöstrand, M., Wei, C., Cook, W., Johnsson, K., Pollack, P. S., Stahre, C., & Hirshberg, B. (2017). Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. Diabetes therapy : research, treatment and education of diabetes and related disorders, 8(3), 587-599. https://doi.org/10.1007/s13300-017-0261-8
Sjöstrand, Mikaela, et al. "Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 8,3 (2017): 587-599. doi: https://doi.org/10.1007/s13300-017-0261-8
Sjöstrand M, Wei C, Cook W, Johnsson K, Pollack PS, Stahre C, Hirshberg B. Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. Diabetes Ther. 2017 Jun;8(3):587-599. doi: 10.1007/s13300-017-0261-8. Epub 2017 Apr 21. PMID: 28432619; PMCID: PMC5446386.
Copy Download .nbib Format: NLM
Share it on

Diabetes Ther. 2017 Jun;8(3):587-599. doi: 10.1007/s13300-017-0261-8. Epub 2017 Apr 21.

Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Mikaela Sjöstrand, Cheryl Wei, William Cook, Kristina Johnsson, Pia S Pollack, Christina Stahre, Boaz Hirshberg

Affiliations

  1. AstraZeneca, Gothenburg, Sweden. [email protected].
  2. AstraZeneca, Gaithersburg, MD, USA.
  3. MedImmune, Gaithersburg, MD, USA.
  4. AstraZeneca, Gothenburg, Sweden.

PMID: 28432619 PMCID: PMC5446386 DOI: 10.1007/s13300-017-0261-8

Abstract

INTRODUCTION: This meta-analysis of data from 14 phase 2 and 3, double-blind, randomized, controlled 12- and 24-week studies (N = 4632) summarizes saxagliptin efficacy in patients with type 2 diabetes (T2D) across treatment regimens.

METHODS: Patients received saxagliptin 5 mg/d or control as either monotherapy (n = 1196 vs placebo), add-on therapy (n = 2139 vs placebo and n = 514 vs uptitrated sulfonylurea), or initial combination therapy (n = 619 vs control monotherapy). Patients with renal impairment received saxagliptin 2.5 mg/d or placebo (n = 164).

RESULTS: Mean baseline glycated hemoglobin (A1C) ranged from 8.07% to 9.43% for the saxagliptin and control groups across treatment regimens. A1C reduction from baseline was greater with saxagliptin versus control for all studies combined (mean treatment difference [95% CI]: -0.55% [-0.63%, -0.47%]) and when used as monotherapy (-0.52% [-0.63, -0.40%]), add-on (-0.55% [-0.69%, -0.40%] vs placebo; -0.72% [-0.88%, -0.56%] vs uptitrated sulfonylurea), initial combination therapy (-0.54% [-0.73%, -0.35%] vs control monotherapy), and in patients with renal impairment (-0.42% [-0.75%, -0.09%]). Similar reductions in A1C versus control were noted for patients <65 years (-0.55% [-0.67%, -0.43%]) and ≥65 years (-0.54% [-0.69%, -0.38%]) and for men (-0.54% [-0.69%, -0.40%]) and women (-0.55% [-0.64%, -0.47%]) across treatment regimens. More patients achieved A1C <7% (39% vs 23%) and A1C ≤6.5% (24% vs 14%) with saxagliptin than with placebo or active-control treatment. Saxagliptin versus control was associated with a reduction in glucagon area under the curve (AUC) from baseline and increases in insulin AUC, C-peptide AUC, and the homeostasis model assessment of β-cell function.

CONCLUSION: Results of this meta-analysis demonstrate the consistency of saxagliptin efficacy in different subgroups of patients with T2D across treatment regimens.

FUNDING: AstraZeneca.

Keywords: Dipeptidyl peptidase-4 (DPP-4) inhibitor; Incretin enhancer; Meta-analysis; Saxagliptin; Type 2 diabetes

References

  1. N Engl J Med. 2013 Oct 3;369(14):1317-26 - PubMed
  2. N Engl J Med. 2016 Jul 28;375(4):311-22 - PubMed
  3. Diabetes Metab Res Rev. 2014 Oct;30(7):556-69 - PubMed
  4. Diabetes Care. 2009 Sep;32(9):1649-55 - PubMed
  5. Diabetes Care. 2009 Nov;32 Suppl 2:S151-6 - PubMed
  6. Curr Med Res Opin. 2012 Apr;28(4):513-23 - PubMed
  7. Curr Med Res Opin. 2011 Apr;27(4):863-9 - PubMed
  8. Diabetes Obes Metab. 2015 May;17(5):487-94 - PubMed
  9. Diabetes Care. 2013 Aug;36(8):2271-9 - PubMed
  10. Diabetes Care. 2016 Jan;39 Suppl 1:S52-9 - PubMed
  11. Lancet. 1998 Sep 12;352(9131):837-53 - PubMed
  12. Diabetes Metab Res Rev. 2012 Mar;28(3):268-75 - PubMed
  13. J Clin Endocrinol Metab. 2009 Dec;94(12):4810-9 - PubMed
  14. JAMA. 2015 Sep 8;314(10):1021-9 - PubMed
  15. J Clin Endocrinol Metab. 2000 Oct;85(10):3575-81 - PubMed
  16. Diabetes Care. 2015 Mar;38(3):376-83 - PubMed
  17. N Engl J Med. 2016 Nov 10;375(19):1834-1844 - PubMed
  18. Diabetes Obes Metab. 2011 Jun;13(6):523-32 - PubMed
  19. Int J Clin Pract. 2009 Sep;63(9):1395-406 - PubMed
  20. N Engl J Med. 2013 Oct 3;369(14):1327-35 - PubMed
  21. JAMA. 2007 Jul 11;298(2):194-206 - PubMed
  22. Endocr Pract. 2016 Jan;22(1):84-113 - PubMed
  23. Diabetes Res Clin Pract. 2011 Nov;94(2):217-24 - PubMed
  24. N Engl J Med. 2015 Jul 16;373(3):232-42 - PubMed
  25. Diabetes Res Clin Pract. 2014 Feb;103(2):137-49 - PubMed
  26. Diabetologia. 2001 Sep;44 Suppl 2:S14-21 - PubMed
  27. Diabetes Obes Metab. 2011 Sep;13(9):850-8 - PubMed
  28. Clin Interv Aging. 2013;8:419-30 - PubMed
  29. N Engl J Med. 2015 Nov 26;373(22):2117-28 - PubMed
  30. N Engl J Med. 2015 Jun 4;372(23):2197-206 - PubMed
  31. Circulation. 2016 Jan 26;133(4):e38-360 - PubMed
  32. Diabet Med. 2013 Dec;30(12):1472-6 - PubMed
  33. Diabetes Obes Metab. 2012 Oct;14(10):918-26 - PubMed
  34. Diabetes Obes Metab. 2009 Jun;11(6):611-22 - PubMed
  35. N Engl J Med. 2008 Oct 9;359(15):1577-89 - PubMed
  36. Diabetes Obes Metab. 2014 May;16(5):443-50 - PubMed
  37. Cell Metab. 2006 Mar;3(3):153-65 - PubMed
  38. Curr Med Res Opin. 2009 Oct;25(10):2401-11 - PubMed
  39. Diabetologia. 1986 Jan;29(1):46-52 - PubMed
  40. Lancet. 2015 May 23;385(9982):2067-76 - PubMed
  41. Diabetes Obes Metab. 2015 Jul;17(7):630-8 - PubMed
  42. Clin Interv Aging. 2014 Sep 04;9:1479-87 - PubMed
  43. Diabetes Obes Metab. 2008 May;10(5):376-86 - PubMed
  44. BMC Endocr Disord. 2014 Feb 24;14:17 - PubMed
  45. Eur J Biochem. 1993 Jun 15;214(3):829-35 - PubMed
  46. Diabetes. 2001 Jul;50(7):1588-97 - PubMed
  47. N Engl J Med. 2015 Dec 3;373(23 ):2247-57 - PubMed
  48. Diabetol Metab Syndr. 2012 Jul 24;4(1):36 - PubMed

Publication Types